BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 18083041)

  • 21. [Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
    Tang CH; Liu XQ; Gao HJ; Li JJ; Guo WF; Li XY; Wang WX; Liu B; Qu LL; Wang WW
    Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):143-7. PubMed ID: 20403247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
    Kudo K; Hotta K; Bessho A; Nogami N; Kozuki T; Kuyama S; Inoue K; Harita S; Okada T; Gemba K; Fujii M; Takigawa N; Oda N; Tanimoto M; Kiura K
    Cancer Chemother Pharmacol; 2016 May; 77(5):1005-9. PubMed ID: 27029623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.
    Chou LS; Garey J; Oishi K; Kim E
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S15-22. PubMed ID: 17239286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.
    Feld R; Sridhar SS; Shepherd FA; Mackay JA; Evans WK;
    J Thorac Oncol; 2006 May; 1(4):367-76. PubMed ID: 17409886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temporal dependence of the effect of radiation on erlotinib-induced skin rash.
    Lacouture ME; Hwang C; Marymont MH; Patel J
    J Clin Oncol; 2007 May; 25(15):2140; author reply 2141. PubMed ID: 17513824
    [No Abstract]   [Full Text] [Related]  

  • 28. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.
    Kumarakulasinghe NB; Syn N; Soon YY; Asmat A; Zheng H; Loy EY; Pang B; Soo RA
    Oncotarget; 2016 Dec; 7(51):85542-85550. PubMed ID: 27907909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
    Pérez-Soler R; Chachoua A; Hammond LA; Rowinsky EK; Huberman M; Karp D; Rigas J; Clark GM; Santabárbara P; Bonomi P
    J Clin Oncol; 2004 Aug; 22(16):3238-47. PubMed ID: 15310767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).
    Brahmer JR; Lee JW; Traynor AM; Hidalgo MM; Kolesar JM; Siegfried JM; Guaglianone PP; Patel JD; Keppen MD; Schiller JH
    Eur J Cancer; 2014 Jan; 50(2):302-8. PubMed ID: 24246704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
    Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
    Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    Wheatley-Price P; Ding K; Seymour L; Clark GM; Shepherd FA
    J Clin Oncol; 2008 May; 26(14):2350-7. PubMed ID: 18467727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
    Silvestri GA; Rivera MP
    Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number.
    Szutowicz-Zielińska E; Konopa K; Kowalczyk A; Suszko-Każarnowicz M; Duchnowska R; Szczęsna A; Ratajska M; Sowa A; Limon J; Biernat W; Burzykowski T; Jassem J; Dziadziuszko R
    Oncotarget; 2017 Mar; 8(10):17270-17278. PubMed ID: 27924059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
    Milton DT; Azzoli CG; Heelan RT; Venkatraman E; Gomez JE; Kris MG; Krug LM; Pao W; Rizvi NA; Dunne M; Miller VA
    Cancer; 2006 Sep; 107(5):1034-41. PubMed ID: 16878326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
    Burotto M; Manasanch EE; Wilkerson J; Fojo T
    Oncologist; 2015 Apr; 20(4):400-10. PubMed ID: 25795635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Newly recognized ocular side effects of erlotinib.
    Methvin AB; Gausas RE
    Ophthalmic Plast Reconstr Surg; 2007; 23(1):63-5. PubMed ID: 17237697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.